ACM
VKTX icon

ADAR1 Capital Management’s Viking Therapeutics VKTX Stock Holding History

ADAR1 Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
574,038
+346,321
+152% +$11.2M 1.02% 20
2026
Q1 		$7.41M Buy
227,717
+201,223
+760% +$6.47M 0.44% 56
2025
Q4 		$932K Sell
26,494
-149,425
-85% -$5.29M 0.07% 137
2025
Q3 		$4.62M Buy
175,919
+108,106
+159% +$3.23M 0.43% 51
2025
Q2 		$1.8M Buy
67,813
+8,400
+14% +$221K 0.28% 58
2025
Q1 		$1.43M Buy
59,413
+50,113
+539% +$1.58M 0.27% 67
2024
Q4 		$374K Buy
9,300
+2,200
+31% +$125K 0.07% 123
2024
Q3 		$450K Sell
7,100
-84,127
-92% -$4.94M 0.07% 121
2024
Q2 		$4.84M Buy
91,227
+76,826
+533% +$5.04M 0.91% 21
2024
Q1 		$1.18M Sell
14,401
-239,750
-94% -$10.7M 0.27% 56
2023
Q4 		$4.73M Buy
+254,151
New +$3.32M 1.69% 14

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ADAR1 Capital Management's VKTX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Viking Therapeutics (VKTX) stake by 152% in Q2 2026, buying an estimated $11.2M and bringing the position to 574,038 shares worth $22.4M. The position accounts for 1.02% of the portfolio, ranked #20.

ADAR1 Capital Management first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • ADAR1 Capital Management held 574,038 shares of Viking Therapeutics worth $22.4M as of Q2 2026.
  • ADAR1 Capital Management bought 346,321 Viking Therapeutics shares in Q2 2026, an estimated $11.2M.
  • Viking Therapeutics made up 1.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #20 holding.
  • ADAR1 Capital Management first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.